more

AxoGen, Inc. (AXGN)

(Delayed Data from NSDQ)

$15.31 USD

-0.28 (-1.80%)

Updated Nov 20, 2019 04:00 PM ET

Pre-Market: $15.30 -0.01 (-0.07%) 7:57 PM ET

Add to portfolio

Zacks Rank:

3-Hold 3

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1 2 3 4 5 S&P	Strong Buy Buy Hold Sell Strong Sell 500	24.62% 17.69% 9.40% 5.11% 2.01% 10.65%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

F Value | D Growth | A Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Industry Rank:

Top 30% (77 out of 254)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

AxoGen, Inc. (AXGN) Quote Overview » News » AxoGen, Inc. (AXGN) Zacks News

Zacks News

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 06,2019

AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGN

earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank

Earnings Preview: AxoGen (AXGN) Q3 Earnings Expected to Decline

by Zacks Equity Research Published on October 30,2019

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN

consensus-outlook earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate

AxoGen (AXGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research Published on August 06,2019

AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGN

earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank

Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline

by Zacks Equity Research Published on July 30,2019

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN

consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on May 08,2019

AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGN

earnings earnings-estimates earnings-outlook earnings-surprise energy industry-outlook zacks-consensus-estimate zacks-rank

Analysts Estimate AxoGen (AXGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on May 01,2019

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN

consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on February 13,2019

DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.

MASI DXCM WMGI AXGN

medical

What's in Store for Humana (HUM) Stock in Q4 Earnings?

by Zacks Equity Research Published on February 04,2019

Higher enrollment and strong segmental results are expected to help Humana (HUM) in fourth-quarter earnings.

AXGN MOH HUM THC

medical

AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on October 29,2018

AxoGen (AXGN) delivered earnings and revenue surprises of 0.00% and 0.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

AXGN

earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank

AxoGen (AXGN) Q3 Earnings Preview: What's in the Cards?

by Zacks Equity Research Published on October 22,2018

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN

consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate